APA (7th ed.) Citation

Kapelios, C. J., Lainscak, M., Savarese, G., Laroche, C., Seferovic, P., Ruschitzka, F., . . . Auer, J. (2019). Sacubitril/valsartan eligibility and outcomes in the ESC‐EORP‐HFA Heart Failure Long‐Term Registry: Bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM‐HF trial, ESC guidelines, and real world. European Journal of Heart Failure, 21(11), 1383. https://doi.org/10.1002/ejhf.1532

Chicago Style (17th ed.) Citation

Kapelios, Chris J., et al. "Sacubitril/valsartan Eligibility and Outcomes in the ESC‐EORP‐HFA Heart Failure Long‐Term Registry: Bridging Between European Medicines Agency/Food and Drug Administration Label, the PARADIGM‐HF Trial, ESC Guidelines, and Real World." European Journal of Heart Failure 21, no. 11 (2019): 1383. https://doi.org/10.1002/ejhf.1532.

MLA (9th ed.) Citation

Kapelios, Chris J., et al. "Sacubitril/valsartan Eligibility and Outcomes in the ESC‐EORP‐HFA Heart Failure Long‐Term Registry: Bridging Between European Medicines Agency/Food and Drug Administration Label, the PARADIGM‐HF Trial, ESC Guidelines, and Real World." European Journal of Heart Failure, vol. 21, no. 11, 2019, p. 1383, https://doi.org/10.1002/ejhf.1532.